AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 72 filers reported holding AMYLYX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $92,392 | +6.2% | 5,046 | +25.1% | 0.00% | +33.3% |
| Q2 2023 | $87,035 | -26.5% | 4,035 | 0.0% | 0.00% | -40.0% |
| Q1 2023 | $118,387 | -22.6% | 4,035 | 0.0% | 0.01% | -16.7% |
| Q4 2022 | $152,927 | +98.6% | 4,035 | +46.0% | 0.01% | +100.0% |
| Q3 2022 | $77,000 | +450.0% | 2,764 | +271.5% | 0.00% | +200.0% |
| Q2 2022 | $14,000 | +40.0% | 744 | 0.0% | 0.00% | – |
| Q1 2022 | $10,000 | – | 744 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 2,515,868 | $46,065,543 | 15.30% |
| Alpha Wave Global, LP | 853,262 | $15,623,227 | 9.88% |
| Saturn V Capital Management LP | 886,143 | $16,225,278 | 6.79% |
| Ally Bridge Group (NY) LLC | 272,690 | $4,992,954 | 5.86% |
| Altium Capital Management LP | 534,700 | $9,790,357 | 5.11% |
| Boxer Capital, LLC | 2,084,000 | $38,158,040 | 2.03% |
| Octagon Capital Advisors LP | 695,000 | $12,725,450 | 1.96% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 295,000 | $5,398,500 | 1.82% |
| Tri Locum Partners LP | 282,862 | $5,179,203 | 1.66% |
| Perceptive Advisors | 2,688,873 | $49,233,265 | 1.64% |